The Relevance of Gynecologic Oncologists to Provide High-Quality of Care to Women with Gynecological Cancer by Lucas Minig et al.
January 2016 | Volume 5 | Article 3081
Mini Review
published: 14 January 2016
doi: 10.3389/fonc.2015.00308
Frontiers in Oncology | www.frontiersin.org
Edited by: 
Sarah M. Temkin, 
National Cancer Institute, USA
Reviewed by: 
Alexandra Resch, 
Medical University Vienna, Austria 
Teresa Diaz-Montes, 
Mercy Medical Center, USA
*Correspondence:
Lucas Minig  
lucasminig@yahoo.com
Specialty section: 
This article was submitted to 
Women's Cancer, 






Minig L, Padilla-Iserte P and 
Zorrero C (2016) The Relevance of 
Gynecologic Oncologists to Provide 
High-Quality of Care to Women with 
Gynecological Cancer. 
Front. Oncol. 5:308. 
doi: 10.3389/fonc.2015.00308
The Relevance of Gynecologic 
Oncologists to Provide High-Quality 
of Care to women with Gynecological 
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Gynecologic oncologists have an essential role to treat women with gynecological can-
cer. It has been demonstrated that specialized physicians who work in multidisciplinary 
teams to treat women with gynecological cancers are able to obtain the best clinical and 
oncological outcomes. However, the access to gynecologic oncologists for women with 
suspected gynecological cancer is scarce. Therefore, this review analyzes the impor-
tance of specialized care of women with ovarian, cervical, and endometrial cancer. In 
addition, the role of gynecologic oncologists who offer fertility-sparing treatment as well 
as their role in assisting general gynecologists and obstetricians is also reviewed.
Keywords: gynecologic oncologists, ovarian cancer, vulvar cancer, endometrial cancer, cervical cancer, 
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inTRODUCTiOn
It is estimated that over a million new cases and half million deaths are due to gynecological cancers 
that occur annually worldwide (1). Even though general gynecologists commonly treat these diseases 
across the world, the sub-specialization in gynecologic oncology has been progressively increasing 
in developed countries since 1972 (2, 3).
According to the definition of the American Board of Obstetrics and Gynecologist, gynecologic 
oncologist is “a specialists in obstetrics and gynecology who is prepared to provide consultation on 
comprehensive management of patients with gynecologic cancer and who works in an institutional 
setting wherein all the effective forms of cancer therapy are available” (4).
Gynecologic oncologists have an essential role when treating women with gynecological cancer. 
They are in a unique position to enrich the global health community with opportunities for education, 
training, and policymaking as it pertains to women’s cancers. In addition, they are in a privileged 
position to make decisions regarding the integration and sequencing of all modalities of treatment.
Specialized physicians who work in multidisciplinary teams to treat women with gynecological 
cancers obtain the best clinical and oncological outcomes (5–7). We think that by this approach, 
gynecologic oncologists not only play an important role in performing an optimal surgery but they 
can also provide a better overall quality of care by having a holistic conception of women. However, 
in countries with a high number of gynecologic oncologists, only a minority of women with 
gynecological cancer receives care by specialized physicians at referral institutions (8). For example, 
it has been demonstrated that approximately one-third of women with ovarian cancer are treated 
by gynecologic oncologists in the U.S. Therefore, this article will review the role of gynecologic 
oncologists who treat women with different gynecological malignancies.
FiGURe 1 | Multidisciplinary team to treat women with gynecological 
cancer.
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OvARiAn CAnCeR
Ovarian cancer probably represents the best example of how a 
well-prepared specialist can positively modify the clinical and 
oncologic outcomes of women. Ovarian cancer is the most aggres-
sive gynecological cancer with a 5-year overall survival of 40% 
(9). There are well-documented independent prognostic factors 
at advanced-stage disease, including tumor histology and grade 
of differentiation, patient’s age, stage of disease, performance 
status, and surgical debulking (10). However, the latter is the 
only modifiable factor, which means that it is amenable for direct 
influence, and therefore, seems to be of the utmost importance 
when considering efforts aiming toward improving outcomes of 
this disease.
The relevance of an adequate surgery was highlighted in 
multiple studies, which associated a significant improvement 
in oncological outcomes after a complete tumor resection at 
the time of primary surgical cytoreduction in comparison with 
cases in which there was some amount of residual disease at the 
end of the surgical procedure (9–11). Thus, according to the last 
Gynecological Cancer InterGroup (GCIG) consensus conference, 
“the mainstay of treatment of advanced ovarian cancer is primary 
surgery aiming at complete tumor resection followed by platinum 
and paclitaxel chemotherapy” (12).
However, the final decision as to whether or not to perform a 
tumor debulking depends on the surgeon’s training and confidence 
(13). Many studies suggest that patients operated on by gynecologic 
oncologists with previous training in cytoreductive techniques are 
more likely to undergo an adequate surgical staging in the early 
stage of the disease, and a better rate of complete cytoreduction 
in advanced stages in comparison with those patients treated by 
general gynecologists or general surgeons (5–7). More specifically, 
when gynecologic oncologists perform the surgery, there are twice 
as many probabilities of obtaining a complete cytoreduction (5). As 
a consequence, according to the results of meta-analyses, patients 
operated on by gynecologic oncologists have significantly better 
oncological outcomes, which resulted in an increased overall 
survival of 10 months, in comparison with those patients treated 
by general gynecologist or general surgeons (5–7).
A recent document launched by the European Society of 
Gynecological Oncology (ESGO) regarding the quality indica-
tors in ovarian cancer surgery states that “Surgery is performed 
by a certified gynecologic oncologist or, in countries where 
certification is not organized, by a trained surgeon dedicated 
to the management of gynecologic cancer (accounting for over 
50% of his practice) or having completed an ESGO accredited 
fellowship. Skills to successfully complete abdominal and pelvic 
surgery procedures necessary to achieve complete cytoreduction 
must be available” (14).
However, ovarian cancer surgery is not an easy task, and it 
requires an adequate institutional support, as well as establishing 
evidence-based clinical guidelines. Even though gynecologic 
oncologists should lead these surgeries, it is recommended to 
work in a multidisciplinary surgical team involving other special-
ists, such as general surgeons, anesthesiologists, and infectologist. 
This strategy is aimed to offer the best quality of care for the 
patient (Figure 1).
enDOMeTRiAL CAnCeR
The majority of endometrial cancers are low-risk disease with 
excellent oncological outcomes (15). Thus, the potential positive 
impact of subspecialty care in endometrial cancer might be more 
difficult to demonstrate (16). However, gynecologic oncologists 
can have an important role in the implementation of minimally 
invasive surgery with their well-known advantages over open 
surgery (17). In this regard, a recent U.S. epidemiological study 
demonstrated that 86% of robotic surgeries for endometrial 
cancer were performed in 19% of the analyzed hospitals. Each 
additional 25 patients (above the mean surgical volume) were 
associated with over a 2.5-fold increase in odds of robotic surgery 
(OR = 2.65, 95% CI: 1.82–3.86; p < 0.0001) (17).
In addition, another epidemiology study performed in the 
U.S. evaluated 18,338 women with endometrial cancer, 4,489 
of whom at stages II–IV (24.3%) (18). Patients who underwent 
surgery by a gynecologic oncologist were more likely to receive 
a more extensive lymph node resection (16 lymph nodes; 22 
vs. 17%; p < 0.001), have more aggressive histologic cell types, 
such as serous and clear-cell (11.6 vs. 6.1%; p < 0.001), presented 
with advanced-stage disease (stages III and IV; 21.9 vs. 14.6%; 
p < 0.001), were more likely to received chemotherapy (22.6 vs. 
12.4%; p < 0.001), as well as to received radiotherapy (38.9 vs. 
30.7%; p < 0.001). In addition, surgery performed by gynecologic 
oncologist was an independent prognostic factor and was associ-
ated with a 30% increase in overall survival in comparison with 
other type of surgeons (HR, 0.71; 95% CI, 0.62–0.82; p < 0.001) 
(18). Other studies did not find significant differences in the 
survival rate, probably because they only included early-stage 
disease (19), or due to the fact that they only analyzed a small 
number of patients (16, 19).
CeRviCAL CAnCeR
Worldwide, cervical cancer accounts for over 500,000 cases and 
275,000 deaths each year (20). However, there is a great disparity 
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among high- and low-income countries due to successful imple-
mentation of cervical cancer screening programs in developed 
countries (21). In addition, the reduction in the incidence of 
cervical cancer should continue with the increased use of human 
papilloma virus (HPV) vaccination (22). Therefore, the majority of 
women with cervical cancer in developed countries are diagnosed 
at early stages with a 5-year overall survival rate of over 90% (23).
No studies have specifically addressed the impact on survival 
of women with early-stage cervical cancer treated by gynecologic 
oncologists. One U.S. epidemiological study, however, studied 
27,660 women with cervical cancer FIGO stage IIB–IVB who were 
treated at hospitals with different case volumes. The study showed 
that the median rate of survival of patients treated at the lowest 
and highest volume centers were 42.3 months (95% CI 39.8–44.8) 
and 53.8 months (50.1–57.5), respectively (p < 0.001). On multi-
variable analysis, higher facility volume independently predicted 
improved survival (p = 0.022), increased likelihood of receiving 
brachytherapy (p < 0.0005) and chemotherapy (p = 0.013), as well 
as shorter time to radiotherapy completion (p < 0.0005) (24).
vULvAR CAnCeR
Squamous cell cancer of the vulva is a rare disease with an annual 
incidence of 2–3/100,000 women (25). There is evidence that 
demonstrates step-by-step nodal metastases in human cancer 
(26). Therefore, the first regional lymph node, called sentinel node, 
receiving lymphatic fluid from the tumor is initially removed. All 
regional lymph nodes are only dissected in case of disease in the 
sentinel node. Thus, this technique significantly reduces the inci-
dence of postoperative complications, such as wound breakdown 
or cellulitis, and long-term morbidity including lymphedema 
(27). However, failure in the sentinel node detection is mainly 
seen when specialists with low case-volume (<10 cases/year) 
perform the procedure (27). Failure of this procedure can mean 
leaving the sentinel node in place, probably with tumor cells and 
with fatal consequences for patients. Therefore, some authors 
recommend that sentinel node detection in patients with vulvar 
cancer should be offered to well-selected patients by well-trained 
and informed gynecologic oncologists who work in centers 
with at least 10 cases/year (27, 28). In addition, it is also recom-
mended that this technique be performed by multidisciplinary 
team involving gynecologic oncologists, specialists in nuclear 
medicine, and specialized pathologists (27).
ROLe OF GYneCOLOGiC 
OnCOLOGiSTS in SPeCiAL 
CiRCUMSTAnCeS
Fertility Preserving Treatment in women 
with Gynecological Cancers
It is estimated that over 21% of women with gynecological cancer 
are diagnosed in their reproductive age (29). In addition, it has 
been demonstrated a continuum increase of women age at first 
pregnancy (30, 31). Both factors explain why fertility preservation 
in women with gynecological cancer is currently a very important 
issue. The recommended treatment for the great majority of 
gynecological cancer includes radical removal of the uterus and 
ovaries, annulling any possibility for future pregnancies. However, 
fertility-sparing treatment in young patients with women’s cancer 
is possible in very select women without compromising long-term 
survival (32). A recent survey of the ESGO revealed that only a 
minority of young women candidates to fertility-sparing treat-
ment is aware of the opportunity to preserve their fertility (33). 
The main reasons include the surgeon’s being unaware, skeptic, or 
untrained to perform fertility-sparing surgical procedures (33). 
Despite the fact that fertility-sparing surgery is technically not 
difficult (except for radical trachelectomy for cervical cancer), a 
more complicated task can be to select the appropriate candidate 
for such specific treatment. Therefore, according to an ESGO 
statement, these patients should be managed in a multidisciplinary 
team coordinated by gynecologic oncologists in conjunction with 
medical reproductive endocrinologists, perinatologists, patholo-
gist, psychologists, and assisted reproductive specialists (33).
Surgical Assistance to General 
Gynecologists and Obstetricians
Even though gynecologic oncologists are intensively trained in 
all aspects of women’s cancer care, their main area of expertise is 
focused on performing complex surgical procedures. Therefore, 
their role in clinical practice often extends beyond women’s can-
cer. For instance, they can be of assistance to general gynecolo-
gists/obstetricians at certain moments during difficult surgical 
procedures, such as being a surgical resource to obstetricians 
during challenging peripartum hemorrhage, (34–36) as well as 
in cases of complex pelvic anatomy or pathological placenta-
tion (37). A recent study performed at Massachusetts General 
Hospital revealed that gynecologic oncologists can assist general 
gynecologists at the time of intraoperative consultation in 98 
out of 794 benign gynecological surgical procedures (12.3%). 
The main reasons for unplanned consultation included adhesive 
disease, bowel injury, ureter visualization, cancer, and bleeding 
control (34).
CenTRALiZATiOn OF CARe – 
MULTiDiSCiPLinARY MAnAGeMenT
Gynecological cancer is a challenging, complex, and multidis-
ciplinary disease. It is not only important how well trained the 
physicians are but also how many physicians of different special-
ties are involved (38). The concept of the holistic conception of 
patient care under a multidisciplinary team approach is crucial 
from the diagnosis to the demise of the disease, and this model 
should not be restricted to the operating room setting.
A correct collaboration with dedicated pathologists, medical 
oncologists, radiotherapists, biologists, palliative care specialists 
might help avoid unnecessary mismanagements, and therefore, 
reinforce the holistic conception of patients with gynecological 
cancer with an improvement on their perceived quality of care. 
Moreover, the recent molecular biology, genetic, and immunol-
ogy discoveries are opening new optimistic frontiers for the future 
treatment and cure of this disease. Many authors agree that close 
exchanges between the clinical practice and basic research are 
FiGURe 2 | Multidisciplinary care in a gynecological cancer unit.
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crucial for consolidating these progresses (39, 40) (Figure 2). A 
recent meta-analysis demonstrated that women with gynecologi-
cal malignancies who receive care from a multidisciplinary team 
by specialized physicians live for a significantly longer period of 
time (7).
Centralization of care in women with gynecological cancer 
is another crucial issue. In some regions, gynecologic oncology 
cases have been centralized (41) in centers with higher patient 
volumes and interdisciplinary collaboration (42). These centers 
receive referrals from less-specialized hospitals within a network, 
region, or defined catchment area. Under this model of care, 
women are referred to specialized units, which are a team built 
by multiple specialized physicians focused on the comprehensive 
care of women affected by gynecological cancer. Every case is 
discussed inside in a multidisciplinary tumor board where the 
best strategy of treatment is based on multiple points of views, 
taking into consideration all aspects regarding each individual 
patient expectancy beyond the disease itself (Figure 2).
Results of different studies consistently show that patients with 
ovarian cancer treated at high-volume hospitals receive better 
quality of care, which is accomplished by better surgical staging 
and better optimal cytoreduction rate (5–7), as well as better 
chemotherapy administration rate and schemes (43, 44).
One study, performed in England, showed that the survival 
of patients with gynecologic cancer improved significantly after 
centralization in comparison with the pre-centralization period 
(hazard ratio: 0.71; 95% confidence interval: 0.64–0.79) (45). 
Similar findings were also reported for cervical, endometrial, 
and ovarian cancer after the implementation of the U.K. National 
Health Service cancer plan in 2000 (46).
Despite the consensus recommendations (12) and the advan-
tages previously explained, population-based studies indicate 
that access to specialist care in gynecologic oncology for women 
with suspected gynecological cancer is uncommon (47–49). 
Reports from countries such as U.S. (8, 50) and U.K. (49, 51) have 
showed that over 60–80% of patients with advanced stage ovar-
ian cancer are treated in low-volume hospitals by low-volume 
surgeons (8, 52, 53).
Common barriers to the quality of cancer care have been 
identified by multiple investigators and include the extremes of 
age, minority race, low socioeconomic status, rural residence, 
patient’s and physician’s unawareness of gynecologic oncologist 
resources, ineffective recognition of the disease, and third-party 
payers (8, 47).
FeLLOwSHiP-TRAininG PROGRAM
Gynecologic oncologists have also an important role in teach-
ing and educating fellow colleagues. Physicians who want to 
be gynecologic oncologists need to undergo a long and specific 
period of training and education process. After finishing medi-
cine school, physicians must complete a 4- to 5-year residency-
training program in obstetrics and gynecology. Then, they need 
to be accepted in accredited referral institutions to complete their 
specific fellowship-training program for 2–4 more years. The 
training, skills, and knowledge base required of a gynecologic 
oncologist are rapidly expanding. In addition to the original areas 
of radical pelvic surgery, chemotherapy, radiation therapy, and 
pathology, new areas of training include radical upper abdominal 
surgery, minimally invasive and robotic surgery, translational 
medicine and research, and palliative medicine (54).
In 1972, the first gynecologic oncologic fellowship-training 
programs were introduced in the U.S. with two accredited fel-
lowships. Since then, 46 fellowship programs exist with 126 
approved positions (55). Currently, there is a uniform system 
of training developed by the American Board of Obstetrics and 
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Gynecologist who provide the training resource documents for 
the development of a curriculum in gynecologic oncology (4). 
Australia, Canada, U.K., and recently, the European Union are 
other examples of renowned gynecologic oncologic fellowship-
training programs around the world (2). However, the number 
of gynecologic oncologists per patient is still scarce worldwide, 
and it is expected that the number of fellowship positions will 
continue to increase through the following years (56).
COnCLUSiOn
When women with gynecological cancers are treated by gyneco-
logic oncologists in referral cancer centers, they are able to 
live longer and with a better quality of life. Therefore, patients 
should be ideally referred to high-volume physicians/hospitals 
to increase their life expectancy as well as its quality. Expanding 
fellowship-training programs worldwide as well as highlighting 
the existence and relevance of gynecologic oncologists in the 
general population and medical community is crucial to increase 
the patient’s accessibility to a specialist’s care.
AUTHOR COnTRiBUTiOnS
All of the three authors of the present paper declare that there 
are no conflicts of interest and have actively participated in the 
study providing input including (1) substantial contributions to 
conception and design, or acquisition of data, or analysis and 
interpretation of data; (2) drafting of the article, or provision of 
critical revision for important intellectual content; and (3) final 
approval of the version to be published.
ReFeRenCeS
1. Sankaranarayanan R, Ferlay J. Worldwide burden of gynecological cancer. In: 
Preedy VR, Watson RR, editors. Handbook of Disease Burdens and Quality of 
Life Measures. New York, NY: Springer (2010). p. 803–23.
2. Gultekin M, Dursun P, Vranes B, Laky R, Bossart M, Grabowski JP, et  al. 
Gynecologic oncology training systems in Europe: a report from the European 
network of young gynaecological oncologists. Int J Gynecol Cancer (2011) 
21(8):1500–6. doi:10.1097/IGC.0b013e3182202d17 
3. Cohn DE, Roney JD, O’Malley DM, Valmadre S. Residents’ perspectives on 
surgical training and the resident-fellow relationship: comparing residency 
programs with and without gynecological oncology fellowships. Int J Gynecol 
Cancer (2008) 18(1):199–204. doi:10.1111/j.1525-1438.2007.00986.x 
4. American Board of Obstetrics And Gynecology (2015). Available from: http://
www.abog.org/publications/Program%20Requirements-GO-Sept%202014.
pdf#search=“special%20requirements”
5. Vernooij F, Heintz P, Witteveen E, van der Graaf Y. The outcomes of ovarian 
cancer treatment are better when provided by gynecologic oncologists and in 
specialized hospitals: a systematic review. Gynecol Oncol (2007) 105(3):801–12. 
doi:10.1016/j.ygyno.2007.02.030 
6. du Bois A, Rochon J, Pfisterer J, Hoskins WJ. Variations in institutional 
infrastructure, physician specialization and experience, and outcome in 
ovarian cancer: a systematic review. Gynecol Oncol (2009) 112(2):422–36. 
doi:10.1016/j.ygyno.2008.09.036 
7. Fung-Kee-Fung M, Kennedy EB, Biagi J, Colgan T, D’Souza D, Elit LM, et al. 
The optimal organization of gynecologic oncology services: a systematic 
review. Curr Oncol (2015) 22(4):e282–93. doi:10.3747/co.22.2482 
8. Bristow RE, Chang J, Ziogas A, Randall LM, Anton-Culver H. High-
volume ovarian cancer care: survival impact and disparities in access for 
advanced-stage disease. Gynecol Oncol (2014) 132(2):403–10. doi:10.1016/j.
ygyno.2013.12.017 
9. Bookman M, Brady M, McGuire W, Harper P, Alberts D, Friedlander M, et al. 
Evaluation of new platinum-based treatment regimens in advanced-stage 
ovarian cancer: a phase III trial of the Gynecologic Cancer Intergroup. J Clin 
Oncol (2009) 27:1419–25. doi:10.1200/JCO.2008.19.1684 
10. du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. 
Role of surgical outcome as prognostic factor in advanced epithelial ovarian 
cancer: a combined exploratory analysis of 3 prospectively randomized phase 
3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie 
Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d’Investiga-
teurs Nationaux Pour les Etudes des Cancers de l’Ovaire (GINECO). Cancer 
(2009) 115(6):1234–44. doi:10.1002/cncr.24149 
11. Winter WE III, Maxwell GL, Tian C, Carlson JW, Ozols RF, Rose PG, et al. 
Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic 
Oncology Group Study. J Clin Oncol (2007) 25(24):3621–7. doi:10.1200/
JCO.2006.10.2517 
12. Stuart GC, Kitchener H, Bacon M, duBois A, Friedlander M, Ledermann 
J, et  al. 2010 Gynecologic Cancer InterGroup (GCIG) consensus statement 
on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer 
Consensus Conference. Int J Gynecol Cancer (2011) 21(4):750–5. doi:10.1097/
IGC.0b013e31821b2568 
13. Chi DS, Schwartz PE. Cytoreduction vs. neoadjuvant chemotherapy for ovar-
ian cancer. Gynecol Oncol (2008) 111:391–9. doi:10.1016/j.ygyno.2008.07.058 
14. European Society of Gyencological Cancer (ESGO). Document of Quality 
Indicators of Surgery in Advanced Stage Ovarian Cancer (2015). Available from: 
https://drive.google.com/file/d/0B9BpaJiYFz9oNE1PemlKcVY5T1U/view
15. Colombo N, Preti E, Landoni F, Carinelli S, Colombo A, Marini C, et  al. 
Endometrial cancer: ESMO clinical practice guidelines for diagnosis, treat-
ment and follow-up. Ann Oncol (2011) 2011(22 Suppl 6):vi35–9. doi:10.1093/
annonc/mdr374 
16. Kwon JS, Carey MS, Cook EF, Qiu F, Paszat LF. Are there regional differences 
in gynecologic cancer outcomes in the context of a single-payer, public-
ly-funded health care system? A population-based study. Can J Public Health 
(2008) 99:221–6. 
17. Chan JK, Gardner AB, Taylor K, Blansit K, Thompson CA, Brooks R, et al. 
The centralization of robotic surgery in high-volume centers for endometrial 
cancer patients  –  a study of 6560 cases in the U.S. Gynecol Oncol (2015) 
138(1):128–32. doi:10.1016/j.ygyno.2015.04.031 
18. Chan JK, Sherman AE, Kapp DS, Zhang R, Osann KE, Maxwell L, et  al. 
Influence of gynecologic oncologists on the survival of patients with endome-
trial cancer. J Clin Oncol (2011) 29(7):832–8. doi:10.1200/JCO.2010.31.2124 
19. MacDonald OK, Sause WT, Lee RJ, Dodson MK, Zempolich K, Gaffney DK. 
Does oncologic specialization influence outcomes following surgery in early 
stage adenocarcinoma of the endometrium? Gynecol Oncol (2005) 99:730–5. 
doi:10.1016/j.ygyno.2005.07.111 
20. Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Dicker D, 
Pain A, Hamavid H, Moradi-Lakeh M, et al. The global burden of cancer 2013 
JAMA Oncol (2015) 1:505–27. doi:10.1001/jamaoncol.2015.0735 
21. Sankaranarayanan R. Screening for cancer in low- and middle-income coun-
tries. Ann Glob Health (2014) 80(5):412–7. doi:10.1016/j.aogh.2014.09.014 
22. Markowitz LE, Hariri S, Lin C, Dunne EF, Steinau M, McQuillan G, et  al. 
Reduction in human papillomavirus (HPV) prevalence among young women 
following HPV vaccine introduction in the United States, National Health and 
Nutrition Examination Surveys, 2003-2010. J Infect Dis (2013) 208(3):385–93. 
doi:10.1093/infdis/jit192 
23. Quinn MA, Benedet JL, Odicino F, Maisonneuve P, Beller U, Creasman WT, 
et al. Carcinoma of the cervix uteri. FIGO 26th annual report on the results 
of treatment in gynecological cancer. Int J Gynaecol Obstet (2006) 95(Suppl 
1):S43–103. doi:10.1016/S0020-7292(06)60030-1 
24. Lin JF, Berger JL, Krivak TC, Beriwal S, Chan JK, Sukumvanich P, et al. Impact 
of facility volume on therapy and survival for locally advanced cervical cancer. 
Gynecol Oncol (2014) 132(2):416–22. doi:10.1016/j.ygyno.2013.12.013 
January 2016 | Volume 5 | Article 3086
Minig et al. Gynecologic Oncologists to Treat Women Cancers
Frontiers in Oncology | www.frontiersin.org
25. US Cancer Statistics Working Group. United States Cancer Statistics: 2003 
Incidence and Mortality. Rockville, MD: US Department of Health and 
Human Services, Centers for Disease Control and Prevention, and National 
Cancer Institute (2006).
26. Morton DL, Wen DR, Wong JH, Economou JS, Cagle LA, Storm 
FK, et  al. Technical details of intraoperative lymphatic mapping for 
early stage melanoma. Arch Surg (1992) 127(4):392–9. doi:10.1001/
archsurg.1992.01420040034005 
27. Van der Zee AG, Oonk MH, De Hullu JA, Ansink AC, Vergote I, Verheijen 
RH, et al. Sentinel node dissection is safe in the treatment of early-stage vulvar 
cancer. J Clin Oncol (2008) 26(6):884–9. doi:10.1200/JCO.2007.14.0566 
28. Levenback CF, Ali S, Coleman RL, Gold MA, Fowler JM, Judson PL, et  al. 
Lymphatic mapping and sentinel lymph node biopsy in women with squa-
mous cell carcinoma of the vulva: a gynecologic oncology group study. J Clin 
Oncol (2012) 30(31):3786–91. doi:10.1200/JCO.2011.41.2528 
29. Jelfs P, Giles G, Shugg D. Cancer in Australia 1986–1988. Cancer Series No 2. 
Australian Institute of Health & Welfare and Australasian Association of Cancer 
Registries. Canberra, ACT: Australian Government Publishing Services (1994).
30. UNECE. Trends in Europe an North America. Mean Age of Women at the Birth 
of the First Child. The Statistical Yearbook of the Economic Commission for 
Europe. Geneva: UNECE (2005).
31. Frejka T, Sardon JP. First birth trends in developed countries. Demogr Res 
(2006) 15:147–80. doi:10.4054/DemRes.2006.15.6 
32. Tomao F, Peccatori F, Pup LD, Franchi D, Zanagnolo V, Panici PB, et al. Special 
issues in fertility preservation for gynecologic malignancies. Crit Rev Oncol 
Hematol (2015). doi:10.1016/j.critrevonc.2015.08.024 
33. Kesic V, Rodolakis A, Denschlag D, Schneider A, Morice P, Amant F, et al. 
Fertility preserving management in gynecologic cancer patients: the need 
for centralization. Int J Gynecol Cancer (2010) 20(9):1613–9. doi:10.1111/
IGC.0b013e3181f936ff 
34. Aviki EM, Rauh-Hain JA, Clark RM, Hall TR, Berkowitz LR, Boruta DM, 
et  al. Gynecologic Oncologist as surgical consultant: intraoperative consul-
tations during general gynecologic surgery as an important focus of gyne-
cologic oncology training. Gynecol Oncol (2015) 137(1):93–7. doi:10.1016/j.
ygyno.2015.01.536 
35. Skupski DW, Lowenwirt IP, Weinbaum FI, Brodsky D, Danek M, Eglinton 
GS. Improving hospital systems for the care of women with major obstet-
ric hemorrhage. Obstet Gynecol (2006) 107(5):977–83. doi:10.1097/01.
AOG.0000215561.68257.c5 
36. Tadesse W, Farah N, Hogan J, D’Arcy T, Kennelly M, Turner MJ. Peripartum 
hysterectomy in the first decade of the 21st century. J Obstet Gynaecol (2011) 
31(4):320–1. doi:10.3109/01443615.2011.560300 
37. Turner MJ. Peripartum hysterectomy: an evolving picture. Int J Gynaecol 
Obstet (2010) 109(1):9–11. doi:10.1016/j.ijgo.2009.12.010 
38. Fung-Kee-Fung M, Kennedy EB, Biagi J, Colgan T, D’Souza D, Elit LM, et al. 
An organizational guideline for gynecologic oncology services. Int J Gynecol 
Cancer (2015) 25(4):551–8. doi:10.1097/IGC.0000000000000400 
39. Annunziata CM, Azad N, Dhamoon AS, Whiteley G, Kohn EC. Ovarian 
cancer in the proteomics era. Int J Gynecol Cancer (2008) 18(Suppl 1):1–6. 
doi:10.1111/j.1525-1438.2007.01096.x 
40. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, et al. 
Use of proteomic patterns in serum to identify ovarian cancer. Lancet (2002) 
359(9306):572–7. doi:10.1016/S0140-6736(02)07746-2 
41. Aune G, Torp SH, Syversen U, Hagen B, Tingulstad S. Ten years’ experience 
with centralized surgery of ovarian cancer in one health region in Norway. Int 
J Gynecol Cancer (2012) 22(2):226–31. doi:10.1097/IGC.0b013e31823589ef 
42. Marth C, Hiebl S, Oberaigner W, Winter R, Leodolter S, Sevelda P. Influence 
of department volume on survival for ovarian cancer: results from a 
prospective quality assurance program of the Austrian Association for 
Gynecologic Oncology. Int J Gynecol Cancer (2009) 19:94–102. doi:10.1111/
IGC.0b013e31819915cb 
43. Paulsen T, Kjaerheim K, Kaern J, Tretli S, Trope C. Improved short-term 
survival for advanced ovarian, tubal, and peritoneal cancer patients oper-
ated at teaching hospitals. Int J Gynecol Cancer (2006) 16(Suppl 1):11–7. 
doi:10.1111/j.1525-1438.2006.00319.x 
44. Tingulstad S, Skjeldestad FE, Hagen B. The effect of centralization of pri-
mary surgery on survival in ovarian cancer patients. Obstet Gynecol (2003) 
102:499–505. doi:10.1016/S0029-7844(03)00579-9 
45. Crawford R, Greenberg D. Improvements in survival of gynaecological 
cancer in the Anglia region of England: are these an effect of centralisation 
of care and use of multidisciplinary management? BJOG (2012) 119:160–5. 
doi:10.1111/j.1471-0528.2011.02961.x 
46. Rachet B, Maringe C, Nur U, Quaresma M, Shah A, Woods LM, et  al. 
Population-based cancer survival trends in England and Wales up to 2007: 
an assessment of the NHS cancer plan for England. Lancet Oncol (2009) 
10(4):351–69. doi:10.1016/S1470-2045(09)70028-2 
47. Carney ME, Lancaster JM, Ford C, Tsodikov A, Wiggins CL. A popu-
lation-based study of patterns of care for ovarian cancer: who is seen by a 
gynecologic oncologist and who is not? Gynecol Oncol (2002) 84:36–42. 
doi:10.1006/gyno.2001.6460 
48. Grossi M, Quinn MA, Thursfield VJ, Francis PA, Rome RM, Planner RS, et al. 
Ovarian cancer: patterns of care in Victoria during 1993-1995. Med J Aust 
(2002) 177(1):11–6. 
49. Olaitan A, Weeks J, Mocroft A, Smith J, Howe K, Murdoch J. The surgical 
management of women with ovarian cancer in the south west of England. Br 
J Cancer (2001) 85:1824–30. doi:10.1054/bjoc.2001.2196 
50. Goff BA, Matthews BJ, Wynn M, Muntz HG, Lishner DM, Baldwin LM. 
Ovarian cancer: patterns of surgical care across the United States. Gynecol 
Oncol (2006) 103(2):383–90. doi:10.1016/j.ygyno.2006.08.010 
51. Jolly K, Parry J, Rouse A, Stevens A. Volumes of cancer surgery for breast, 
colorectal and ovarian cancer 1992-97: is there evidence of increasing 
sub-specialization by surgeons? Br J Cancer (2001) 84:1308–13. doi:10.1054/
bjoc.2001.1794 
52. Elit L, Bondy SJ, Paszat L, Przybysz R, Levine M. Outcomes in surgery for ovar-
ian cancer. Gynecol Oncol (2002) 87(3):260–7. doi:10.1006/gyno.2002.6834 
53. Vernooij F, Heintz APM, Witteveen E, van der Heiden-van der Loo M, 
Coebergh JW, van der Graaf Y. Specialized care and survival of ovarian cancer 
patients in The Netherlands: nationwide cohort study. J Natl Cancer Inst (2008) 
100:399–406. doi:10.1093/jnci/djn033 
54. Gershenson DM. The future of gynecologic oncology: are we headed for 
super-specialization? Gynecol Oncol (2011) 122(1):3–4. doi:10.1016/j.
ygyno.2011.04.017 
55. American Board of Obstetrics And Gynecology (2015). Available from: 
https://www.abog.org/new/program.aspx?type=4
56. Wallace AH, Havrilesky LJ, Valea FA, Barnett JC, Berchuck A, Myers ER. 
Projecting the need for gynecologic oncologists for the next 40 years. Obstet 
Gynecol (2010) 116(6):1366–72. doi:10.1097/AOG.0b013e3181fc3a22 
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
Copyright © 2016 Minig, Padilla-Iserte and Zorrero. This is an open-access article 
distributed under the terms of the Creative Commons Attribution License (CC BY). 
The use, distribution or reproduction in other forums is permitted, provided the 
original author(s) or licensor are credited and that the original publication in this 
journal is cited, in accordance with accepted academic practice. No use, distribution 
or reproduction is permitted which does not comply with these terms.
